74205-15-5

Usage

Uses

Used in Pharmaceutical Industry:
1-(3-Methoxyphenyl)cyclobutanecarbonitrile is used as a key intermediate in the synthesis of various pharmaceuticals for its potential biological and pharmacological activities. Its unique structure allows it to interact with different biological targets, making it a promising candidate for the development of new drugs.
Used in Agrochemical Industry:
In the agrochemical industry, 1-(3-Methoxyphenyl)cyclobutanecarbonitrile is utilized as an intermediate in the production of agrochemicals. Its properties contribute to the development of effective compounds for agricultural applications, such as pesticides and herbicides, enhancing crop protection and yield.
Used in Research and Development:
1-(3-Methoxyphenyl)cyclobutanecarbonitrile is employed as a valuable compound in research and development for its potential interactions with various biological targets. Scientists and researchers study its properties and activities to explore its applications in creating new drugs and other important compounds, further expanding its uses across different industries.

Upstream product

• 19924-43-7 3-methoxyphenylacetonitrile 
• 109-64-8 1,3-dibromo-propane 

Downstream Products

• 74205-43-9 1-(3-methoxy-phenyl)-cyclobutanecarboxylic acid 
• 92902-95-9 C-[1-(3-Methoxy-phenyl)-cyclobutyl]-methylamine 
• 803640-24-6 sec-Butyl-[1-(3-methoxy-phenyl)-cyclobutylmethyl]-amine 
• 709604-36-4 Diethyl-[1-(3-methoxy-phenyl)-cyclobutylmethyl]-amine 
• 732206-01-8 Ethyl-[1-(3-methoxy-phenyl)-cyclobutylmethyl]-amine 
• 61492-38-4 (2S,5R,6R)-6-{[1-(3-Methoxy-phenyl)-cyclobutanecarbonyl]-amino}-3,3-dimethyl-7-oxo-4-thia-1-aza-bicyclo[3.2.0]heptane-2-carboxylic acid 

Relevant academic research and scientific papers

Synthesis method of arylcyclobutane compound

The present invention discloses a method for synthesizing an arylcyclobutane compound to 1eq phenylacetonitrile and 1.1eq 1-bromo-3-chloropropane as raw material, N,N- dimethylacetamide as a solvent, plus 2.5eq sodium hydride, under the protection of iner

Iridium-Catalyzed Enantioselective C(sp3)–H Borylation of Cyclobutanes

We herein report the first example of iridium-catalyzed enantioselective C(sp3)–H borylation of cyclobutanes using benzoxazoline as the directing group. The combination of a chiral bidentate boryl ligand and an iridium precursor has found to effectively catalyze C(sp3)–H borylation to afford a variety of cyclobutylboronates with good to excellent enantioselectivities. We also demonstrate the synthetic utility of the current method by converting the stereogenic C—B bond to other functionalities.

Oxadiazole Amine Derivative Compounds as Histone Deacetylase 6 Inhibitor, and the Pharmaceutical Composition Comprising the same

The present invention relates to a novel compound having an activity of inhibiting histone deacetylase 6 (HDAC6), an optical isomer thereof or a pharmaceutically acceptable salt thereof, a use thereof for preparation of a drug for treatment, a pharmaceutical composition comprising the same, a treatment method using the composition, and a method for preparing the same. The novel compound, an optical isomer thereof or a pharmaceutically acceptable salt thereof according to the present invention has an activity of inhibiting histone deacetylase 6 (HDAC6), and is effective for preventing or treating HDAC6-related diseases, including infectious diseases; neoplasm; endocrine, nutritional and metabolic diseases; mental and behavior disorders; nerve disorders; eye and adnexa diseases; cardiovascular diseases; respiratory diseases; digestive organ diseases; skin and subcutaneous tissue diseases; musculoskeletal and connective tissue diseases; or congenital malformation, deformation and chromosomal abnormality.COPYRIGHT KIPO 2017

Discovery and development of potent and selective inhibitors of histone methyltransferase G9a

G9a is a histone lysine methyltransferase responsible for the methylation of histone H3 lysine 9. The discovery of A-366 arose from a unique diversity screening hit, which was optimized by incorporation of a propyl-pyrrolidine subunit to occupy the enzyme

5-lipoxygenase inhibitors

Novel compounds having the ability to inhibit 5-lipoxygenase enzyme and having the following formula I: STR1 and the pharmaceutically acceptable salts thereof, wherein Ar1 is a heterocyclic moiety which is selected from imidazolyl, pyrrolyl, py